What Is Happening With SP600125

d. (n = 15) or 600 mg imatinib q.d. (n = 2). Mean treatment duration was 102 months (range 69�C129) in 2011. The authors found that serum levels of parathyroid hormone increased significantly in the patients between 2007 and 2011, and seven out of 17 patients had secondary hyperparathyroidism in 2011. However, the mean areal and volumetric BMDs were stable in the CML patients over the 4-year-observation period. Moreover, the CML patients had significantly higher volumetric BMD in the cortical compartment when compared with controls in 2011 and 2007. http://www.selleck.cn/products/SP600125.html Thus, despite a high incidence of secondary hyperparathyroidism, there were no signs of osteoporosis or osteomalacia in imatinib-treated CML patients as suggested earlier. Chronic myeloid leukemia (CML) is treated with the tyrosine kinase inhibitor imatinib that inhibits the oncoprotein BCR-ABL [1]. In addition, imatinib inhibits http://www.selleckchem.com/products/smoothened-agonist-sag-hcl.html several other tyrosine kinases, e.g., c-ABL, PDGFR��/��, c-KIT, and CSF1R [2]. The long-term consequences of inhibition of these tyrosine kinases are a concern. In vitro studies have showed an inhibitory effect of imatinib on osteoclast activity and proliferation of mesenchymal stem cells (MSCs) [3�C12]. The authors have previously shown that CML patients treated with imatinib have signs of suppressed bone turnover, i.e., low levels of serum calcium and bone markers, and an increase in PTH level while increased BMD [13]. Furthermore, O'Sullivan et al. [14] recently reported a 2-year prospective study, in which, BMD was stable or increased in nine imatinib-treated CML patients. However, the long-term effects of imatinib therapy on BMD and bone quality are lacking. To address this, the authors prospectively followed the patients and controls included in their previous study for 4 years (Table I). The mean-serum levels of ionized calcium, phosphate, and magnesium had not changed significantly between 2007 and 2011 in the patient or control group (Table http://www.selleckchem.com/products/epz015666.html II). In 2007, the patients had significantly lower mean serum levels of ionized calcium and phosphate when compared with controls, however in 2011, there were no significant differences. Serum magnesium continued to be lower in the patients when compared with controls in 2011 (P